
Hoth Therapeutics (HOTH) Stock Forecast & Price Target
Hoth Therapeutics (HOTH) Analyst Ratings
Bulls say
Hoth Therapeutics Inc. is making notable progress in its clinical-stage initiatives, with total operating expenses increasing only modestly, indicating disciplined expense management while advancing its lead asset, HT-001. The company's dual-track strategy, targeting supportive oncology and metabolic diseases, highlights its commitment to developing solutions for significant unmet medical needs and could generate incremental value from its joint venture programs. Promising early results, with over 65% of trial participants reporting reductions in pain and pruritus, suggest broad symptom improvement, bolstering confidence in Hoth's multi-program strategy and its potential regulatory advancements.
Bears say
Hoth Therapeutics Inc. reported a significant net loss of approximately $4.11 million for the most recent quarter, translating to a loss of $(0.30) per share. In the second quarter of 2025, the company recorded no revenues as anticipated, with total operating expenses decreasing to $2.2 million compared to $3.4 million in the prior quarter, indicating ongoing financial strain despite reduced costs. The continuous absence of revenue generation in conjunction with persistent losses raises concerns regarding the company's financial sustainability and growth potential in the near term.
This aggregate rating is based on analysts' research of Hoth Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Hoth Therapeutics (HOTH) Analyst Forecast & Price Prediction
Start investing in Hoth Therapeutics (HOTH)
Order type
Buy in
Order amount
Est. shares
0 shares